Since the new Cancer Drugs Fund began in July 2016, just over 17,600 patients have been registered to receive treatment for 48 medicines. Below is a table showing the breakdown by medicine. Drug Number Atezolizumab 34 Bendamustine 2,321 Bevacizumab 1,595 Blinatumomab 29 Bortezomib 105 Bosutinib 39 Brentuximab 346 Cabozantinib 154 Carfilzomib 45 Ceritinib 15 Cetuximab 1,708 Clofarabine 82 Crizotinib 127 Daratumumab 35 Dasatinib 107 Eribulin 347 Everolimus 370 Ibrutinib 1,067 Ipilimumab/Nivolumab 97 Ixazomib 119 Lenvatinib Fewer than 10 Nab-paclitaxel 134 Nelarabine 45 Nivolumab 541 Obinutuzumab 33 Olaratumumab 199 Osimertinib 255 Palbociclib 413 Panitumumab 392 Pemetrexed 37 Pembrolizumab 1,604 Pertuzumab 1,739 Pegylated liposomal doxorubicin 48 Pomalidomide 380 Ponatinib 88 Radium-223 Dichloride 243 Regorafenib 74 Ribociclib 29 Sorafenib 871 Sunitinib 71 Talimogene laherparepvec Fewer than 10 Temsirolimus Fewer than 10 Trastuzumab Emtansine 673 Trametinib/Dabrafenib 172 Trifluridine and tipiracil 444 Vandetanib 40 Venetoclax 118 Vismodegib 217 Source: NHS England. Information provided from 31 July 2016 to end of January 2018 (latest data available). Note: Numbers lower than 10 are rounded-up to avoid releasing potentially patient identifiable data, as per NHS England’s data protection commitments.